

# 1 SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of 2 Immunodeficiency

3 Yijia Li<sup>\*1 2 3</sup> , Manish C. Choudhary<sup>\*1</sup> , James Regan<sup>\*1</sup> , Julie Boucau<sup>4</sup> , Anusha Nathan<sup>4 5</sup> ,  
4 Tessa Speidel<sup>6</sup> , May Yee Liew<sup>2 7</sup> , Gregory E. Edelstein<sup>1</sup> , Yumeko Kawano<sup>1</sup> , Rockib Uddin<sup>2 7</sup> ,  
5 Rinki Deo<sup>1</sup> , Caitlin Marino<sup>4</sup> , Matthew A. Getz<sup>4</sup> , Zahra Reynold<sup>2</sup> , Mamadou Barry<sup>2</sup> , Rebecca F.  
6 Gilbert<sup>2</sup> , Dessie Tien<sup>2</sup> , Shruti Sagar<sup>2</sup> , Tammy D. Vyas<sup>2</sup> , James P. Flynn<sup>1</sup> , Sarah P.  
7 Hammond<sup>2</sup> , Lewis A. Novack<sup>1</sup> , Bina Choi<sup>1</sup> , Manuela Cernadas<sup>1</sup> , Zachary S. Wallace<sup>2</sup> , Jeffrey  
8 A. Sparks<sup>1</sup> , Jatin M. Vyas<sup>2 4</sup> , Michael S. Seaman<sup>6</sup> , Gaurav D. Gaiha<sup>2 4</sup> , Mark J. Siedner<sup>#2</sup> ,  
9 Amy K. Barczak<sup>#2 4</sup> , Jacob E. Lemieux<sup>#2 7</sup> , Jonathan Z. Li<sup>#1</sup>

10

## 11 Affiliations:

- 12 1. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 13 2. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 14 3. University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- 15 4. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
- 16 5. Program in Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of  
17 Technology, Boston, MA 02115, USA
- 18 6. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical  
19 School, Boston, MA, USA
- 20 7. Broad Institute of MIT and Harvard, Cambridge, MA, USA

21

22 \*, # Equal contribution

23

## 24 Funding:

25 This work was supported by the National Institutes of Health (U19 AI110818), the Massachusetts  
26 Consortium for Pathogen Readiness SARS-CoV-2 Variants Program and the Massachusetts General

27 Hospital Department of Medicine. Drs. JA Sparks and ZS Wallace are supported by the National Institute  
28 of Arthritis and Musculoskeletal and Skin Diseases (R01 AR080659). Dr. JA Sparks is also supported by  
29 the Llura Gund Award funded by the Gordon and Llura Gund Foundation. Dr. GD Gaiha is supported by  
30 the NIH (DP2AI154421, R01AI176533 and DP1DA058476), the Bill and Melinda Gates Foundation,  
31 Burroughs Wellcome Career Award for Medical Scientists and Howard Goodman Fellowship. Dr. JZ Li  
32 was also supported by a grant from Merck. Dr. Y Li was supported by Rustbelt CFAR (Case Western  
33 Reserve University/University Hospitals Cleveland Medical Center and University of Pittsburgh, P30  
34 AI036219). The BSL3 laboratory where viral culture work was performed is supported by the Harvard  
35 CFAR (P30 AI060354). The funders had no role in the study design; in the collection, analysis, and  
36 interpretation of data; in the writing of the manuscript; or in the decision to submit the manuscript for  
37 publication.

38 **Abstract**

39 Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for  
40 prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent COVID-  
41 19 remain incompletely understood. In this study, we performed detailed viro-immunologic  
42 analyses of a prospective cohort of participants with COVID-19. The median time to nasal viral  
43 RNA and culture clearance in the severe hematologic malignancy/transplant group (S-HT) were  
44 72 and 21 days, respectively, which were significantly longer than clearance rates in the severe  
45 autoimmune/B-cell deficient (S-A), non-severe, and non-immunocompromised groups  
46 ( $P < 0.001$ ). Participants who were severely immunocompromised had greater SARS-CoV-2  
47 evolution and higher risk of developing antiviral treatment resistance. Both S-HT and S-A  
48 participants had diminished SARS-CoV-2-specific humoral, while only the S-HT group had  
49 reduced T cell-mediated responses. This highlights the varied risk of persistent COVID-19  
50 across immunosuppressive conditions and suggests that suppression of both B and T cell  
51 responses results in the highest contributing risk of persistent infection.

## 52 **Introduction**

53 Coronavirus Disease 2019 (COVID-19) vaccinations have drastically transformed the landscape  
54 of the COVID-19 pandemic by offering significant protection against infection acquisition, and  
55 severe diseases<sup>1,2</sup>, and ultimately have averted tens of millions of deaths<sup>3</sup>. Unfortunately, not all  
56 individuals respond to vaccination equally well, and immunocompromised individuals can have  
57 poor vaccine responses<sup>4,5</sup> and worse COVID-19-related outcomes<sup>6,7</sup>. Each new variant of  
58 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) brings risks of resistance to  
59 current treatments, particularly targeted antibody therapies<sup>8,9</sup>, resistance to vaccine-induced and  
60 naturally acquired immunity<sup>9,10</sup>, and increased transmissibility<sup>10</sup>. Immunocompromised  
61 individuals have been observed to harbor detectable SARS-CoV-2 virus for longer than non-  
62 immunocompromised individuals<sup>11-13</sup>. Such individuals represent a potential origin of novel  
63 SARS-CoV-2 variants as persistent infection has been associated with accelerated viral  
64 evolution<sup>11,13</sup>. However, the immunocompromised state is composed of a range of conditions  
65 and immune defects. These defects that predispose to persistent COVID-19 remain under-  
66 characterized. While there have been a number of case reports of persistent COVID-19 in  
67 immunosuppressed individuals<sup>11-16</sup> showing excessively prolonged viral shedding, persistent  
68 disease, and intra-host virological genetic diversity, there remains a need for larger scale  
69 studies with a comprehensive virologic and immunologic characterization to better elucidate the  
70 immunologic risk factors for and mechanisms of persistent infection. To this end, we hereby  
71 present a detailed longitudinal virological and immunological analysis of a cohort of  
72 immunocompromised and non-immunocompromised participants with SARS-CoV-2 infection  
73 with the goal of characterizing the virologic spectrum of persistent infection and exploring the  
74 immunologic determinants that predispose to its occurrence.

## 75 **Results**

### 76 **Participant Characteristics**

77 Fifty-six immunocompromised participants and 184 non-immunocompromised participants  
78 enrolled in the POSITIVES longitudinal cohort study were included in this analysis <sup>17-19</sup>.

79 Demographic information and key viral characteristics are shown in Table 1.

80 Immunocompromised participants were significantly older than non-immunocompromised  
81 controls (median 55 vs 46 years,  $P=0.001$ ), and more likely to receive monoclonal antibody  
82 (mAb) and/or antiviral treatment against SARS-CoV-2. The two groups had comparable sex,  
83 race, and ethnicity profiles and a similar median time from symptom onset/first positive COVID-  
84 19 test to enrollment (5 vs 4 days). We further subdivided immunocompromised participants into  
85 the severe hematologic-oncology/transplant (S-HT,  $n=12$ ), severe autoimmune/B-cell deficient  
86 (S-A,  $n=13$ ) and non-severe (NS,  $n=31$ ) groups (refer to Supplementary Tables 1 and 2 for  
87 detailed categorization). Three participants died due to severe COVID-19 or COVID-19 related  
88 complications, all of whom were in the immunocompromised sub-group (S-HT and S-A).

89

### 90 **Delayed Viral Clearance in Hematologic Oncology and Transplant Participants**

91 We first aimed to characterize viral dynamics in the upper respiratory tract in participants with  
92 different categories of immunocompromising conditions. Immunocompromised and non-  
93 immunocompromised participants had similar peak vRNA levels (5.1, 5.1, 4.9, and 5.7  $\log_{10}$   
94 SARS-CoV-2 copies/ml in S-HT, S-A, NS and non-immunocompromised groups,  $P=0.5$ ).

95 However, the rates of nasal vRNA decay were significantly different between the  
96 immunocompromising categories, with the S-HT group demonstrating significantly slower viral  
97 clearance compared to other groups (Fig. 1a and 1b). Median time to nasal vRNA clearance in  
98 the S-HT group was 72 days (95% confidence interval [CI] 5, not available [NA]) compared to 7  
99 (6, NA) days for the S-A, 11 (8, 16) days for the NS and 11 (10, 12) days for the non-  
100 immunocompromised group (Fig. 1b, log-rank  $P=0.005$ ). Similarly, the S-HT group experienced

101 significant delay in the clearance of culturable virus (Fig. 1c and 1d). Median time to viral  
102 culture clearance in the S-HT group was 21 days (95%CI 5, NA) compared to 6.5 (5, NA) days  
103 for the S-A group, 6 days (5, 7) for the NS group and 7 days (6, 7) for the non-  
104 immunocompromised group (Fig. 1d, log-rank  $P=0.0007$ , Fig. 1d). After 30 days from symptom  
105 onset or first positive test, 50%, 15%, and 6.5% of participants from S-HT, S-A and NS groups  
106 had detectable vRNA, compared to 0% in non-immunocompromised group ( $P<0.0001$ ,  
107 Extended Data Fig. 1a). In addition, 33% of S-HT and 8.3% of S-A participants still had  
108 culturable virus, compared to 0% in the NS and non-immunocompromised groups after 30 days  
109 ( $P<0.0001$ , Extended Data Fig. 1b). Compared to the non-immunocompromised group, the S-  
110 HT group was significantly associated with delayed vRNA clearance (adjusted hazard ratio  
111 [aHR] for viral clearance, 0.35, 95% CI 0.13-0.91,  $P=0.03$ ) and culturable virus clearance (aHR  
112 0.34 for viral clearance, 95% CI 0.15-0.76,  $P=0.009$ ), after adjusting for demographics, number  
113 of vaccinations and antiviral use (Table 2).

114

### 115 **Increased Viral Evolution and Genetic Diversity in Immunocompromised Participants**

116 We used gene-specific next-generation sequencing approach to quantify the number of unique  
117 intra-host single-nucleotide variants (iSNVs) in the S gene present at  $>3\%$  frequency within  
118 each sample. This analysis was limited to participants with a viral genome available both at  
119 baseline and at least one follow-up timepoint. Severely immunocompromised (S-HT and S-A)  
120 participants harbored a greater number of iSNVs over time compared to NS and non-  
121 immunocompromised group participants, although these comparisons did not reach statistic  
122 significance (Fig. 2a). To evaluate viral diversity, we calculated the average pairwise distance  
123 both at the nucleotide and at the amino-acid level. Nucleotide average pairwise distance was  
124 significantly higher in the severe immunocompromised (S-HT and S-A) group compared to  
125 either non-severe ( $4.0E-4$  vs  $8.2E-5$ ,  $P<0.001$  Dunn's test with Benjamini-Hochberg adjustment)  
126 or non-immunocompromised groups ( $4.0E-4$  vs  $2.3E-5$ ,  $P<0.001$ , Fig. 2b). Similar results were

127 obtained when the average pairwise distances were calculated for amino acids (Extended Data  
128 Fig. 2a). Among participants with longitudinal sequences, 39% of the participants in  
129 immunocompromised group versus 12% in the non-immunocompromised group had evidence  
130 of viral nucleotide changes (Fisher's exact  $P < 0.001$ , Fig. 2c). These nucleotide changes were  
131 distributed across the entire length of the S gene (Fig. 2d).

132

### 133 **Increased Risk of Treatment-Emergent Resistance to Anti-SARS-CoV-2 Monoclonal** 134 **Antibody Therapy**

135 Deep sequencing analysis of Spike gene was carried out to evaluate the dynamics of mutation  
136 emergence in the presence of mAb treatment as earlier reports have shown evidence of mAb  
137 resistance emergence both in immunocompromised and non-immunocompromised  
138 participants<sup>13,20-29</sup>. In total, 34 participants across different study groups received mAb therapy,  
139 10 in S-HT, 9 in S-A, 5 in NS, and 10 in non-immunocompromised groups (Details in  
140 Supplemental Table 3). Of these, we were able to evaluate the risk of resistance emergence in  
141 a subset of participants for whom sequences were available at both baseline and at least one  
142 follow-up time point. Five out of nine (56%) severely immunocompromised participants (S-HT  
143 and S-A) developed mAb-specific resistance mutations (Extended data Fig. 2b). This was a  
144 significantly higher rate than that found in the non-severe or non-immunocompromised groups  
145 (0/11 [0%] combined, Fisher's exact  $P = 0.008$ ) (Fig 2e).

146

### 147 **Suboptimal Humoral Response in Severely Immunocompromised Participants**

148 We next characterized the antibody response in immunocompromised and non-  
149 immunocompromised participants. In participants whose serum sample was available ( $n = 94$ ),  
150 including those who had previously received monoclonal antibodies, we found no significant  
151 difference in nAb titers between the different immunocompromised and non-  
152 immunocompromised groups at early and later sampling time points, although this analysis may

153 have been limited due to individuals who received anti-SARS-CoV-2 monoclonal antibody  
154 infusion before sample collection (either therapeutic or pre-exposure prophylaxis) (Fig. 3a and  
155 3b). The non-immunocompromised group had a significant increase in anti-ancestral and anti-  
156 variant spike nAb levels during follow-up, whereas we did not observe a significant increase in  
157 antibody levels in the immunocompromised group (Fig. 3a and 3b). However, after excluding  
158 individuals with exposure to mAb therapies, the severe immunocompromised group showed no  
159 significant changes in either anti-ancestral or anti-variant Spike nAb levels, while the non-severe  
160 immunocompromised group demonstrated a moderate increase and the non-  
161 immunocompromised group demonstrated the greatest increase in nAb levels, plateauing at day  
162 25-30 (Fig. 3c and d).

163  
164 In a generalized estimating equation (GEE) model adjusted for factors associated with nAb  
165 levels, severely immunocompromised participants were only able to mount 0.18-fold  
166 (approximately 5-fold lower) of the anti-ancestral Spike antibody (95% CI 0.05-0.60) and 0.08-  
167 fold (approximately 12-fold lower) of the anti-variant Spike antibody (95% CI 0.03-0.22)  
168 compared to non-immunocompromised participants (Extended Fig. 3a, b). Non-severe  
169 immunocompromised status was not associated with significant differences in nAb changes  
170 from acute to post-infection, compared to non-immunocompromised group. In the whole cohort,  
171 each dose of vaccinations prior to SARS-CoV-2 infection was associated with 1.70-fold (95% CI  
172 1.25 to 2.30) and 1.35-fold (95% CI 1.01 to 1.79) increase in anti-ancestral and anti-variant  
173 Spike antibody levels, respectively (Extended Fig. 3ab).

174  
175 We also evaluated binding antibody against nucleocapsid protein because this assay is not  
176 affected by monoclonal antibody use. Similar to nAb, individuals in the S-HT and S-A sub-  
177 groups had significantly blunted increases in nucleocapsid binding Ab development from acute  
178 to post-infection, and significantly lower binding Ab levels compared to NS and non-



179 immunocompromised groups (Fig. 3e). Longitudinally, binding Ab levels in NS and non-  
180 immunocompromised groups plateaued around day 20-25 at a level of 1-1.5 log<sub>10</sub> IU/ml, while  
181 S-HT/S-A groups exhibited delayed development to a level below 1 log<sub>10</sub> IU/ml after day 50 (Fig.  
182 3f).

183

## 184 **T Cell Responses**

185 In a recent study, Apostolidis et al. demonstrated elevated spike-specific CD8<sup>+</sup> T cell responses  
186 in COVID-19 mRNA vaccinated participants with multiple sclerosis receiving anti-CD20  
187 treatment compared to healthy controls<sup>30</sup>. However, it remains largely unknown if different types  
188 and levels of immunosuppression are associated with a similar T cell immunophenotype. To this  
189 end, we profiled the T cell effector function using enzyme-linked immunosorbent spot (ELISpot)  
190 and antigen-specific proliferation assay for a selected group of participants based on sample  
191 availability. The non-immunocompromised group had lower interferon gamma (IFN- $\gamma$ ) producing  
192 units per million cells upon stimulation at both blood draws (acute infection 0-14 days, and post-  
193 acute 15-60 days after symptom onset or first positive COVID-19 test) compared to both NS and  
194 S-A groups in response to both ancestral and variant-specific Spike peptide pools (Fig. 4a).  
195 Individuals in the S-A group tended to have the highest levels of CD4<sup>+</sup> and CD8<sup>+</sup> T cell  
196 proliferation upon spike peptide pool stimulation, especially compared to the S-HT and non-  
197 immunocompromised individuals (Fig. 4bc and Extended Fig. 4). In longitudinal analysis, the S-  
198 HT group showed poor functional CD4<sup>+</sup> and CD8<sup>+</sup> T cell proliferation, despite a comparable IFN-  
199  $\gamma$  secretion level compared to the non-immunocompromised group (Fig. 4d). In contrast, the S-A  
200 group showed robust T cell proliferation over time, in response to both ancestral and variant-  
201 specific spike peptide pools compared to all other groups, suggestive of either an antigen-  
202 stimulated compensatory effect in the setting of B cell deficiency or a medication-related T cell  
203 priming.

## 204 **Discussion**

205 Understanding viral and immune control characteristics of COVID-19 infection is crucial to our  
206 ability to care for immunocompromised individuals at greatest risk of persistent and severe  
207 infection. Moreover, it can guide public health interventions and shed light on vaccine  
208 development that protects immunocompromised individuals. In this study, we performed an in-  
209 depth virologic and immunologic evaluation of a cohort of immunocompromised and non-  
210 immunocompromised individuals. We demonstrated a hierarchy of immunocompromised  
211 conditions that increase the risk of delayed viral clearance and SARS-CoV-2 evolution.  
212 Furthermore, we identified the varied risk of persistent COVID-19 across immunosuppressive  
213 conditions and suppression of both B and T cell responses in those at the highest risk of  
214 persistent infection. Specifically, we found that individuals with a history of hematological  
215 malignancy and organ transplant demonstrated the greatest delay in viral clearance that may be  
216 mediated by suppression of both the B and T cell responses. In contrast, those with B cell  
217 immunodeficiency had an intermediate risk of chronic infection in the setting of an immune  
218 response showing compensatory heightened levels of SARS-CoV-2-specific T cell function.  
219  
220 Our cohort study confirmed findings from prior case reports and case series. In a review by  
221 Dioverti et al., the authors summarized cases of persistent COVID-19 lasting from  
222 approximately one month to one year<sup>31</sup>. These included a spectrum of immunocompromised  
223 hosts from individuals with solid organ transplants, hematological malignancy<sup>14,20,22,23,25,29,32-36</sup>,  
224 and autoimmune diseases receiving immunosuppressive therapies. However,  
225 immunocompromise is a broad spectrum and, until now it has not been clear which  
226 immunosuppressive conditions represent the greatest risk for persistent infection. The results of  
227 our study provide critical insight as to the hierarchy of risk for delayed SARS-CoV-2 RNA and  
228 culture clearance, and viral evolution. Specifically, we found that demonstrated that individuals  
229 with solid organ transplant and hematological malignancy are associated with the longest period

230 of viral RNA and culturable viral shedding, followed by severely immunocompromised  
231 participants with autoimmune conditions receiving B-cell depleted therapy and/or those with B  
232 cell deficiency. Participants with mild non-severe immunocompromise, such as those with  
233 autoimmune diseases receiving anti-tumor necrosis factor (TNF) treatment, had similar viral  
234 shedding dynamics to non-immunocompromised participants.

235  
236 There have been several prior case reports of immunosuppressed individuals with chronic  
237 COVID-19 and accumulation of viral polymorphisms and drug resistance mutations<sup>13,14,21,27,34</sup>,  
238 but there has been little in the way of more systematic evaluation of viral evolution. In this study,  
239 we used S gene-specific deep sequencing to assess longitudinal viral evolution and diversity.  
240 Our results show that severe immunosuppression is associated with increased viral evolution  
241 and diversification. In addition, severe immunocompromised hosts had a greater risk of  
242 developing treatment-emergent resistance mutations to mAb therapy when compared to non-  
243 immunocompromised group participants. These findings highlight the potential for  
244 immunocompromised individuals to serve as a source for SARS-CoV-2 evolution and drug  
245 resistance, consistent with isolated reports of immunocompromised hosts implicated in the  
246 emergence of highly mutated SARS-CoV-2 variants<sup>13,15,16,24,28,37-40</sup>. It should be noted though  
247 that even within the category of severe immunocompromise, participants demonstrated a range  
248 of viral diversification and evolution patterns, and additional studies are needed to fully assess  
249 the drivers of accelerated viral evolution.

250  
251 Another highlight of our study is our use of in-depth analysis of B and T cell responses,  
252 including SARS-CoV-2-specific neutralizing and binding antibody levels, as well as ELISpot and  
253 T cell proliferation studies. We noted lower levels of neutralizing antibody against both ancestral  
254 virus and variant virus in the severe immunocompromised group (less than 10-20% compared  
255 to non-immunocompromised individuals), after adjusting for vaccination doses, monoclonal

256 antibody use, and demographic confounders. Each additional dose of vaccination is associated  
257 with an approximately 1.5-fold increase in antibody levels in the whole cohort, underscoring the  
258 importance of adherence to COVID-19 vaccination recommendations. However, there is  
259 evidence that non-B-cell immunity may be sufficient for the clearance of SARS-CoV-2. Early in  
260 the pandemic, cases were reported of individuals with X-linked agammaglobulinemia who  
261 developed COVID-19 pneumonia, but subsequently recovered despite a lack of SARS-CoV-2-  
262 specific immunoglobulins<sup>41</sup>. In our study, the risk of chronic infection was highest in S-HT  
263 participants. This group of participants was found to have both suboptimal humoral and cell-  
264 mediated immune responses. The “near-normal” level of effector ELISpot responses in S-HT  
265 individuals, compared to the non-immunocompromised group, is the likely the result of exposure  
266 to high levels of SARS-CoV-2 antigen, while the reduced proliferation demonstrates  
267 compromised functionality. In contrast, the S-A participants had an even more robust SARS-  
268 CoV-2-specific proliferative T-cell responses than the non-immunocompromised group,  
269 indicating increased levels of functional SARS-CoV-2-specific CD8<sup>+</sup> T cell responses, which  
270 was associated with an intermediate risk of chronic infection. These results align with some  
271 intriguing reports that individuals receiving anti-CD20 treatment may demonstrate a stronger T-  
272 cell responses, in particular more robust activation-induced marker-positive CD8<sup>+</sup> T cell  
273 responses<sup>30</sup>. We found that both CD8<sup>+</sup> T cell response and CD4<sup>+</sup> T-cell responses, including  
274 proliferation in response to both ancestral and variant-specific spike peptides, were more  
275 pronounced in S-A group compared to other non-immunocompromised groups. Together with  
276 the results from Apostolidis et al.<sup>30</sup>, our results raise the question of whether individuals with B  
277 cell deficiencies may have a lower risk of persistent SARS-CoV-2 infection due to preserved T  
278 cell function, either as a compensatory mechanism or T cell priming by certain B cell-depleting  
279 therapies.

280

281 There are several limitations to this study. We included a relatively small number of individuals  
282 with malignant hematological conditions or transplant history, and we were able to obtain blood  
283 samples from only a subset of the participants to characterize their humoral and T-cell immunity.  
284 Larger studies are needed to provide greater precision as to extent of immune defect or  
285 immunosuppressive medication that may place patients at the greatest risk of chronic infection  
286 and viral evolution. We also did not analyze markers reflecting innate immunity, including  
287 soluble inflammatory markers and monocyte phenotypes. Our study focused on virologic and  
288 immunologic responses after COVID-19 and it is unclear how these may contribute to  
289 persistence and severity of symptoms. Furthermore, we only evaluated Spike-specific humoral  
290 and cellular immunity, while immunity targeting other structural or non-structural proteins has  
291 been shown to alter disease course<sup>42,43</sup>.

292  
293 In conclusion, in this prospective cohort of well-characterized individuals with acute COVID-19,  
294 we demonstrated a correlation between a hierarchy of immunocompromised conditions and  
295 SARS-CoV-2 viral shedding, viral evolution, and adaptive immunity. Our results highlight the  
296 finding that the risk of chronic SARS-CoV-2 infection is not uniform across immunosuppressive  
297 conditions and provide clarity on which immunosuppression conditions predispose to delayed  
298 SARS-CoV-2 RNA and culture clearance, and viral evolution. The high risk populations  
299 identified in this study may benefit from targeted public health and additional therapeutic  
300 interventions. In addition, the results provide further insights on the humoral and cell-mediated  
301 immune correlates of viral clearance, which is crucial for the development of improved vaccines  
302 and future therapies.

## 303 **Methods**

### 304 **Participant Enrollment and Sample Collection**

305 We enrolled participants with a positive COVID-19 test in the Mass General Brigham Medical  
306 HealthCare System as part of the POSSt-VacclnATIOn Viral CharactERistics Study (POSITIVES)  
307 <sup>17,19</sup> in addition to one immunocompromised participant from our previous study. Each  
308 participant's medical record was reviewed for demographic data, immunosuppression status,  
309 and COVID-19 treatment history by board-certified clinicians. For the POSITIVES study,  
310 participants self-collected anterior nasal swabs every 2-3 days to a total of 6 samples over 2  
311 weeks. Participants with immunocompromised conditions were offered to collect additional  
312 swabs when possible and were followed until they had two consecutive negative PCR tests. For  
313 this one immunocompromised participants reported previously<sup>13</sup>, nasopharyngeal swab was  
314 collected by healthcare providers. In a subset of participants who agreed to provide blood  
315 sample, the first blood draw was done generally before day 15 of symptom onset (acute phase)  
316 or first positive PCR or antigen test for COVID-19, and second blood draw between 15-60 days  
317 after (post-acute phase) (Supplementary Fig. 1). This study was approved by Mass General  
318 Brigham Institutional Review Board and all participants have signed informed consent upon  
319 entry to the study.

320

### 321 **Categorization for Immunocompromised Conditions**

322 Immunocompromised participants were further categorized into the following groups: severe  
323 immunocompromised participants, which were further categorized into severe-hematological  
324 malignancy/transplant patients (S-HT), severe autoimmune patients (S-A, participants with  
325 autoimmune condition receiving B-cell targeting agents or B cell deficiency); and non-severe  
326 immunocompromised participants (NS). This categorization was based on a recent cohort study  
327 which demonstrated a hierarchy of antibody response to COVID-19 vaccinations in different  
328 medical conditions<sup>4,44</sup>. Detailed classification criteria were listed in Supplemental Table 1.

329

### 330 **SARS-CoV-2 Viral Load Assay**

331 SARS-CoV-2 viral RNA (vRNA) were quantified as described previously<sup>45</sup>. Briefly, virions were  
332 pelleted from nasal swab fluid by centrifugation at 21,000g for 2 hours at 4°C. Trizol-LS Reagent  
333 (Thermofisher Scientific) was added to the pellet, vortexed, and incubated on ice for 10 minutes.  
334 Chloroform was added and the solution was vortexed before centrifugation at 21,000g for 15  
335 minutes at 4°C. RNA was isolated from the aqueous layer by isopropanol precipitation and  
336 eluted in DEPC-Treated water (Thermofisher Scientific). SARS-CoV-2 RNA copies were  
337 quantified with an in-house viral load assay using the CDC 2019-nCoV\_N1 primer and probe set  
338 (Integrated DNA Technologies). The efficiency of the RNA extraction and RT-qPCR  
339 amplification was evaluated by quantifying the RCAS RNA recovered from each sample and the  
340 two N1 controls. The importin-8 (IPO8) human housekeeping gene was also amplified and  
341 evaluated as a measure of sample collection quality. Samples were run in triplicate wells for N1,  
342 and in duplicate wells for RCAS and IPO8.

343

### 344 **SARS-CoV-2 Viral Culture Assay**

345 Viral culture was performed as previously reported<sup>17</sup>. Vero-E6 cells (ATCC) maintained in  
346 DMEM(Corning) supplemented with HEPES (Corning), 1X Penicillin (100 IU/mL)/Streptomycin  
347 (100 µg/ml) (Corning), 1X Glutamine (Glutamax, Thermofisher Scientific) and 10% FBS  
348 (MilliporeSigma) were plated 16-20 hours before infection. Each sample consisting of nasal  
349 swab fluid was thawed on ice and filtered through a Spin-X 0.45 µm filter (Corning) at 10,000 xg  
350 for 5 minutes. Before infection the media was changed to DMEM supplemented with HEPES,  
351 1X Antibiotic/Antimycotic (ThermoFisher), 1X Glutamine, 2% FBS and 5 µg/mL of polybrene  
352 (Santa Cruz Biotechnologies). Each filtered sample was then used to inoculate Vero-E6 cells by  
353 spinfection (2,000x g for 1 hour at 37C). Each condition was plated in quadruplicate wells in 1:5

354 dilutions across half the plate. The plates were observed at 7-days post-infection using a light  
355 microscope to check for cytopathogenic effect (CPE) and a median tissue culture infectious  
356 dose (TCID<sub>50</sub>) was calculated for each sample.

357

### 358 **Neutralizing Antibody Responses**

359 Neutralizing activity against SARS-CoV-2 pseudovirus was measured using a single-round  
360 infection assay in 293T/ACE2 target cells<sup>18</sup>. Pseudotyped virus particles were produced in  
361 293T/17 cells (ATCC) by co-transfection of plasmids encoding codon-optimized full-length Spike  
362 (ancestral-D614G, Delta, Omicron-BA.1, Omicron-BA.2, Omicron-BA.4/5), packaging plasmid  
363 pCMV ΔR8.2, and luciferase reporter plasmid pHR' CMV-Luc. Packaging and luciferase  
364 plasmids were kindly provided by Dr. Barney Graham (NIH, Vaccine Research Center). The  
365 293T cell line stably overexpressing the human ACE2 cell surface receptor protein was kindly  
366 provided by Drs. Michael Farzan and Huihui Ma (The Scripps Research Institute). For  
367 neutralization assays, serial dilutions of patient sera were performed in duplicate followed by  
368 addition of pseudovirus. Pooled serum samples from convalescent COVID-19 patients or pre-  
369 pandemic normal healthy serum (NHS) were used as positive and negative controls,  
370 respectively. Plates were incubated for 1 hour at 37°C followed by addition of 293/ACE2 target  
371 cells (1x10<sup>4</sup>/well). Wells containing cells + pseudovirus (without sample) or cells alone acted as  
372 positive and negative infection controls, respectively. Assays were harvested on day 3 using  
373 Promega BrightGlo luciferase reagent and luminescence detected with a Promega GloMax  
374 luminometer. Titers are reported as the dilution of serum that inhibited 50% virus infection (ID<sub>50</sub>  
375 titer). Pseudovirus-based neutralization assays were conducted using ancestral Spike protein,  
376 as well as Delta- and Omicron- (BA.1, BA.2, or BA.4/5) Spike. Anti-variant neutralizing antibody  
377 level (nAb) was determined based on the viral strain each participant was infected with (either  
378 by sequencing or in small proportion, imputed by time of infection when specific strain was  
379 prevalent).



380

### 381 **Nucleocapsid binding antibody assay**

382 Binding antibody against Nucleocapsid protein was measured using Coronavirus Ig Total  
383 Human 11-Plex ProcartaPlex™ Panel (Thermal Fisher) according to the manufacturer's  
384 instruction.

385

### 386 **T Cell Enzyme-linked immunosorbent spot (ELISpot) Assay**

387 Interferon (IFN)- $\gamma$  ELISpot assay was reported in our previous study and were performed  
388 according to the manufacturer's instructions (Mabtech)<sup>46</sup>. Briefly, peripheral blood mononuclear  
389 cells (PBMCs) were incubated with SARS-CoV-2 peptide pools (MGH Peptide Core) at a final  
390 concentration of 0.5 $\mu$ g/ml for 16–18h (100,000-200,000 cells per test). Anti-CD3 (Clone OKT3,  
391 Biolegend, 0.5 $\mu$ g/mL) and anti-CD28 Ab (Clone CD28.2, Biolegend, 0.5 $\mu$ g/mL) were used as  
392 positive controls. To quantify antigen-specific responses, mean spots of the DMSO negative  
393 control wells were subtracted from the positive wells. The results were expressed as spot-  
394 forming units (SFU) per 10<sup>6</sup> PBMCs. Responses were considered positive if the results were  
395 >5 SFU/10<sup>6</sup> PBMCs following control subtraction. If negative DMSO control wells had >30  
396 SFU/10<sup>6</sup> PBMCs or if positive control wells (anti-CD3/anti-CD28 stimulation) did not have >1000  
397 spot-forming units, the results were deemed invalid and excluded from further analysis.

398

### 399 **T Cell Proliferation Assay**

400 T Cell proliferation assay was reported previously<sup>46</sup>. Briefly, PBMCs were incubated in PBS with  
401 0.5  $\mu$ M carboxyfluorescein succinimidyl ester (CFSE; Life Technologies) or CellTrace™ Far Red  
402 (CTFR, Invitrogen) at 37°C for 20 min. Then they were washed and resuspended at 0.5-1  $\times$   
403 10<sup>6</sup>/mL and plated into 96-well U-bottom plates (Corning) in 200  $\mu$ L of media. Peptide pools  
404 were added at a final concentration of 0.5  $\mu$ g/mL, followed by incubation at 37°C, 5% CO<sub>2</sub> for six  
405 days. The PBMC staining antibody panels are in Supplementary Materials. Cells were washed

406 and fixed in 2% paraformaldehyde prior to flow cytometric analysis on a BD LSR II (BD  
407 Biosciences). A positive proliferation response was defined as a percentage of CD3<sup>+</sup>CD4<sup>+</sup> or  
408 CD3<sup>+</sup>CD8<sup>+</sup> CFSE<sup>low</sup> or CTFR<sup>low</sup> cells with at least 1.5x greater than the highest of two negative-  
409 control wells and greater than 0.2% CFSE<sup>low</sup> or CTFR<sup>low</sup> cells in magnitude following  
410 background subtraction.

411

### 412 **SARS-CoV-2 S-gene Sequencing**

413 SARS-CoV-2 viral RNA (vRNA) isolation as described previously<sup>45</sup>. RNA was converted to cDNA  
414 using Superscript IV reverse transcriptase (Invitrogen) as per manufacturer's instructions). Spike  
415 (S) gene amplification was performed using a nested PCR strategy with in-house designed primer  
416 sets targeting codons 1–814 of the Spike as previously described<sup>28</sup>. Further, PCR products from  
417 different individuals were pooled, and Illumina library construction was performed using the  
418 Nextera XT library prep kit (Illumina). Sequencing was performed on the Illumina MiSeq platform  
419 and deep sequencing data analysis was carried out using the Stanford Coronavirus Antiviral &  
420 Resistance Database (CoVDB) platform ([https://covdb.stanford.edu/sierra/sars2/by-  
421 reads/?cutoff=0.01&mixrate=0.01](https://covdb.stanford.edu/sierra/sars2/by-reads/?cutoff=0.01&mixrate=0.01))<sup>47</sup>. Input FASTQ sequence alignment with Wuhan-Hu-1  
422 reference was done using MiniMap2 version 2.22 in CodFreq pipeline  
423 (<https://github.com/hivdb/codfreq>). The output of MiniMap2, an aligned SAM file, is converted to  
424 a CodFreq file by an in-house written Python script using a PySam library (version: 0.18.0) and  
425 further analyzed with the CoVDB. PCR and sequencing runs were performed once with the  
426 appropriate positive and negative controls. For S gene analysis, amino acid variants were then  
427 called at the codon level using perl code and used for resistance interpretation with a 1% limit of  
428 detection. The accuracy of the deep sequencing platforms was evaluated with a control library of  
429 clonal SARS-CoV-2 sequences mixed at known concentrations as described previously<sup>48</sup>.  
430 Mutations detected by next-generation sequencing at <20% of the viral population were labelled  
431 as 'low-frequency' variants as they would largely be missed by traditional Sanger sequencing. A

432 minimum average of 500x sequencing coverage per sample was required for variant calling.  
433 SARS-COV-2 variant calling was done using 3 different variant calling platforms, namely,  
434 CoVDB<sup>47</sup>, Scorpio call v1.2.123 (<https://pangolin.cog-uk.io/>), and Nextclade v.1.13.2  
435 (<https://clades.nextstrain.org/>)<sup>49</sup>. Mutation locations are graphically represented in heatmap for  
436 Spike and in Circos plots for whole genome.

437

### 438 **Single nucleotide variation, and genetic diversity analysis**

439 For assessing intrahost single nucleotide variation (iSNV), data from only those participants were  
440 included for whom sequence data from baseline and at least one follow-up time point were  
441 available. SNV analysis was performed using PASEq SARS-CoV-2 pipeline ([www.paseq.org](http://www.paseq.org)).  
442 Briefly, raw sequence files were quality filtered and adapter-trimmed using trimmomatic (v0.30).  
443 Contaminating sequences were filtered out using BBDMap Suite (v35.76). Duplicated reads were  
444 detected using fastuniq (v1.1). High quality non-redundant reads were then aligned to SARS-  
445 CoV-2 Wuhan reference (NC\_045512.2) using Bowtie2 (v.2.3.2). Resulting alignments were  
446 processed with samtools (v.1.2) and iVar (v1.4.2) to obtain nucleotide variant VCF files.  
447 Nucleotide variants present at 100% frequency of the total viral population at all time points  
448 indicative of lineage defining mutations were excluded from the iSNV analysis. Genetic diversity  
449 between multiple sequences of an individual were assessed by average pairwise distance in  
450 MEGA both at the nucleotide and amino-acid level.

451

### 452 **Statistical Analysis**

453 Categorical variables were summarized using total number and percentage and between-group  
454 differences were evaluated using either chi-squared test or Fisher's exact test when  
455 appropriate. Continuous variables were summarized with median and interquartile ranges and  
456 compared with non-parametric methods (Wilcoxon rank-sum test to compare two groups and  
457 Dunn's test with Benjamini-Hochberg adjustment to compare three or more groups). Within

458 group comparison was conducted using paired Wilcoxon signed-rank test without adjustment for  
459 multiple comparisons. We also used generalized estimating equation (GEE) with Gaussian  
460 estimation to evaluate between-group differences accounting for repeated measurement during  
461 longitudinal follow-up. R (4.3.0) was used for statistical analyses. Two-tailed tests were used for  
462 all the analyses and  $P < 0.05$  was considered statistically significant unless specified otherwise.

## 463 References

- 464 1. El Sahly, H.M., *et al.* Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of  
465 Blinded Phase. *N Engl J Med* **385**, 1774-1785 (2021).
- 466 2. Moreira, E.D., Jr., *et al.* Safety and Efficacy of a Third Dose of BNT162b2 Covid-19  
467 Vaccine. *N Engl J Med* **386**, 1910-1921 (2022).
- 468 3. Watson, O.J., *et al.* Global impact of the first year of COVID-19 vaccination: a  
469 mathematical modelling study. *The Lancet. Infectious diseases* **22**, 1293-1302 (2022).
- 470 4. Haidar, G., *et al.* Prospective Evaluation of Coronavirus Disease 2019 (COVID-19)  
471 Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the  
472 COVID-19 Vaccination in the Immunocompromised Study (COVICS). *Clin Infect Dis* **75**,  
473 e630-e644 (2022).
- 474 5. Wieske, L., *et al.* Humoral responses after second and third SARS-CoV-2 vaccination in  
475 patients with immune-mediated inflammatory disorders on immunosuppressants: a  
476 cohort study. *The Lancet. Rheumatology* **4**, e338-e350 (2022).
- 477 6. Kelly, J.D., *et al.* Incidence of Severe COVID-19 Illness Following Vaccination and  
478 Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines. *Jama* **328**, 1427-  
479 1437 (2022).
- 480 7. Agrawal, U., *et al.* Severe COVID-19 outcomes after full vaccination of primary schedule  
481 and initial boosters: pooled analysis of national prospective cohort studies of 30 million  
482 individuals in England, Northern Ireland, Scotland, and Wales. *Lancet (London, England)*  
483 **400**, 1305-1320 (2022).
- 484 8. Planas, D., *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody  
485 neutralization. *Nature* **596**, 276-280 (2021).
- 486 9. Hoffmann, M., *et al.* SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and  
487 evades antibodies induced by infection and vaccination. *Cell Reports* **36**(2021).
- 488 10. Wang, Q., *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4  
489 and BA.5. *Nature* **608**, 603-608 (2022).
- 490 11. Weigang, S., *et al.* Within-host evolution of SARS-CoV-2 in an immunosuppressed  
491 COVID-19 patient as a source of immune escape variants. *Nat Commun* **12**, 6405  
492 (2021).
- 493 12. Cele, S., *et al.* SARS-CoV-2 prolonged infection during advanced HIV disease evolves  
494 extensive immune escape. *Cell Host Microbe* **30**, 154-162 e155 (2022).
- 495 13. Choi, B., *et al.* Persistence and Evolution of SARS-CoV-2 in an Immunocompromised  
496 Host. *N Engl J Med* **383**, 2291-2293 (2020).

- 497 14. Hensley, M.K., *et al.* Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged  
498 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a  
499 Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. *Clin Infect*  
500 *Dis* **73**, e815-e821 (2021).
- 501 15. Harari, S., *et al.* Drivers of adaptive evolution during chronic SARS-CoV-2 infections. *Nat*  
502 *Med* **28**, 1501-1508 (2022).
- 503 16. Choudhary, M.C., Crain, C.R., Qiu, X., Hanage, W. & Li, J.Z. Severe Acute Respiratory  
504 Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus  
505 Disease 2019 (COVID-19) Persistence and Reinfection. *Clin Infect Dis* **74**, 237-245  
506 (2022).
- 507 17. Boucau, J., *et al.* Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron  
508 (BA.1) Infection. *N Engl J Med* **387**, 275-277 (2022).
- 509 18. Seaman, M.S., *et al.* Vaccine breakthrough infection leads to distinct profiles of  
510 neutralizing antibody responses by SARS-CoV-2 variant. *JCI Insight* **7**(2022).
- 511 19. Siedner, M.J., *et al.* Duration of viral shedding and culture positivity with postvaccination  
512 SARS-CoV-2 delta variant infections. *JCI Insight* **7**(2022).
- 513 20. Avanzato, V.A., *et al.* Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an  
514 Asymptomatic Immunocompromised Individual with Cancer. *Cell* **183**, 1901-1912.e1909  
515 (2020).
- 516 21. Chaguza, C., *et al.* Accelerated SARS-CoV-2 intrahost evolution leading to distinct  
517 genotypes during chronic infection. *Cell reports. Medicine* **4**, 100943 (2023).
- 518 22. Bailly, B., *et al.* Persistent Coronavirus Disease 2019 (COVID-19) in an  
519 Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus  
520 2 (SARS-CoV-2)-Specific Monoclonal Antibodies. *Clin Infect Dis* **74**, 1706-1707 (2022).
- 521 23. Truffot, A., *et al.* SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody  
522 Monotherapy. *Emerging infectious diseases* **27**, 2725-2728 (2021).
- 523 24. Gupta, A., *et al.* Host immunological responses facilitate development of SARS-CoV-2  
524 mutations in patients receiving monoclonal antibody treatments. *The Journal of clinical*  
525 *investigation* **133**(2023).
- 526 25. Baang, J.H., *et al.* Prolonged Severe Acute Respiratory Syndrome Coronavirus 2  
527 Replication in an Immunocompromised Patient. *J Infect Dis* **223**, 23-27 (2021).
- 528 26. Bronstein, Y., *et al.* Evolution of spike mutations following antibody treatment in two  
529 immunocompromised patients with persistent COVID-19 infection. *Journal of medical*  
530 *virology* **94**, 1241-1245 (2022).

- 531 27. Gonzalez-Reiche, A.S., *et al.* Sequential intrahost evolution and onward transmission of  
532 SARS-CoV-2 variants. *Nat Commun* **14**, 3235 (2023).
- 533 28. Choudhary, M.C., *et al.* Emergence of SARS-CoV-2 escape mutations during  
534 Bamlanivimab therapy in a phase II randomized clinical trial. *Nature microbiology* **7**,  
535 1906-1917 (2022).
- 536 29. Kemp, S.A., *et al.* SARS-CoV-2 evolution during treatment of chronic infection. *Nature*  
537 **592**, 277-282 (2021).
- 538 30. Apostolidis, S.A., *et al.* Cellular and humoral immune responses following SARS-CoV-2  
539 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med* **27**,  
540 1990-2001 (2021).
- 541 31. Dioverti, V., Salto-Alejandre, S. & Haidar, G. Immunocompromised Patients with  
542 Protracted COVID-19: a Review of "Long Persisters". *Current transplantation reports*, 1-  
543 10 (2022).
- 544 32. Nussenblatt, V., *et al.* Yearlong COVID-19 Infection Reveals Within-Host Evolution of  
545 SARS-CoV-2 in a Patient With B-Cell Depletion. *J Infect Dis* **225**, 1118-1123 (2022).
- 546 33. Aydillo, T., *et al.* Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for  
547 Cancer. *N Engl J Med* **383**, 2586-2588 (2020).
- 548 34. Gandhi, S., *et al.* De novo emergence of a remdesivir resistance mutation during  
549 treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case  
550 report. *Nat Commun* **13**, 1547 (2022).
- 551 35. Gordon, C.L., *et al.* Defective Severe Acute Respiratory Syndrome Coronavirus 2  
552 Immune Responses in an Immunocompromised Individual With Prolonged Viral  
553 Replication. *Open forum infectious diseases* **8**, ofab359 (2021).
- 554 36. Monrad, I., *et al.* Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection  
555 in Immunocompromised Host Displaying Treatment Induced Viral Evolution. *Open forum*  
556 *infectious diseases* **8**, ofab295 (2021).
- 557 37. Braun, K.M., *et al.* Acute SARS-CoV-2 infections harbor limited within-host diversity and  
558 transmit via tight transmission bottlenecks. *PLoS pathogens* **17**, e1009849 (2021).
- 559 38. Ko, K.K.K., *et al.* Emergence of SARS-CoV-2 Spike Mutations during Prolonged  
560 Infection in Immunocompromised Hosts. *Microbiology spectrum* **10**, e0079122 (2022).
- 561 39. Lythgoe, K.A., *et al.* SARS-CoV-2 within-host diversity and transmission. *Science (New*  
562 *York, N. Y.)* **372**(2021).
- 563 40. Valesano, A.L., *et al.* Temporal dynamics of SARS-CoV-2 mutation accumulation within  
564 and across infected hosts. *PLoS Pathog* **17**, e1009499 (2021).

- 565 41. Soresina, A., *et al.* Two X-linked agammaglobulinemia patients develop pneumonia as  
566 COVID-19 manifestation but recover. *Pediatric allergy and immunology : official*  
567 *publication of the European Society of Pediatric Allergy and Immunology* **31**, 565-569  
568 (2020).
- 569 42. Dangi, T., *et al.* Improved control of SARS-CoV-2 by treatment with nucleocapsid-  
570 specific monoclonal antibody. *The Journal of clinical investigation*, e162282 [Online  
571 ahead of print] (2022).
- 572 43. Kundu, R., *et al.* Cross-reactive memory T cells associate with protection against SARS-  
573 CoV-2 infection in COVID-19 contacts. *Nat Commun* **13**, 80 (2022).
- 574 44. Maneikis, K., *et al.* Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and  
575 early clinical outcomes in patients with haematological malignancies in Lithuania: a  
576 national prospective cohort study. *The Lancet Haematology* **8**, e583-e592 (2021).
- 577 45. Fajnzylber, J., *et al.* SARS-CoV-2 viral load is associated with increased disease  
578 severity and mortality. *Nat Commun* **11**, 5493 (2020).
- 579 46. Nathan, A., *et al.* Structure-guided T cell vaccine design for SARS-CoV-2 variants and  
580 sarbecoviruses. *Cell* **184**, 4401-4413.e4410 (2021).
- 581 47. Tzou, P.L., Tao, K., Pond, S.L.K. & Shafer, R.W. Coronavirus Resistance Database  
582 (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma,  
583 and plasma from vaccinated persons. *PloS one* **17**, e0261045 (2022).
- 584 48. Li, J.Z., *et al.* Impact of pre-existing drug resistance on risk of virological failure in South  
585 Africa. *The Journal of antimicrobial chemotherapy* **76**, 1558-1563 (2021).
- 586 49. Aksamentov, I., Roemer, C., Hodcroft, E.B. & Neher, R.A. Nextclade: clade assignment,  
587 mutation calling and quality control for viral genomes. *The Journal of Open Source*  
588 *Software* **6**, 3773 (2021).
- 589  
590



591 **Figure Legends**

592 **Figure 1. Kinetics of SARS-CoV-2 viral RNA and culturable virus among different**

593 **immunocompromised groups. a**, Upper respiratory viral load decay. Lower level of  
594 quantification (LLOQ) is 10 copies/ml. **b**, Kaplan-Meier estimates of upper respiratory viral  
595 clearance (viral load below LLOQ). **c**, Upper respiratory culturable virus dynamics (50% Tissue  
596 Culture Infectious Dose [TCID<sub>50</sub>]). **d**, Kaplan-Meier estimates of upper respiratory culturable  
597 virus clearance.

598

599 **Figure 2. SARS-CoV-2 intra-host mutations among different immunocompromise groups.**

600 **a**, Number of intra-host single-nucleotide variants (iSNVs) among severe (S-HT in red and S-A  
601 in green), non-severe immunocompromised and non-immunocompromised (None) groups. **b**,  
602 Nucleotide average pairwise distance (APD) among severe (S-HT in red and S-A in green),  
603 non-severe immunocompromised (NS) and non-immunocompromised (None) groups. **c**,  
604 Participants with any nucleotide changes during follow-up. **d**, Heat map showing distribution of  
605 Spike polymorphisms from participants receiving mAb treatment. Each row represents one  
606 participant, while x axis shows amino acid positions in the Spike gene. Different domains of  
607 Spike are shown at the top. Colors indicate frequency of polymorphisms, with blue indicating the  
608 lowest value and red indicating the highest value in the scale. Participants in different study  
609 groups are separated by a red horizontal line. **e**, Proportion of mAb resistance emergence  
610 amongst those treated with mAbs, categorized by those with severe or non-severe/no  
611 immunosuppression. Comparison of iSNV and APD between groups were done using using  
612 Dunn's test with Benjamini-Hochberg P value adjustment. Fisher's exact test was used to  
613 calculate significance between participants with and without viral evolution and further, in  
614 participants with and without mAb treatment specific resistance mutations. Only significant P  
615 values are shown. NTD, N-terminal domain; RBD, receptor binding domain; RBM, receptor  
616 binding motif; S1, subunit 1; S2, subunit 2.

617

618 **Figure 3. Neutralizing antibody (nAb) and Nucleocapsid binding antibody levels among**

619 **different immunocompromised groups. a**, nAb levels (50% inhibitory dilution [ID<sub>50</sub>]) against

620 ancestral Spike protein. **b**, nAb levels against variant-specific Spike protein. **c** and **d**,

621 Longitudinal trajectory of nAb in different immunocompromise groups, including (**c**) or excluding

622 (**d**) monoclonal antibody use. **e**, binding antibody levels against Nucleocapsid protein. **f**,

623 Longitudinal trajectory of binding antibody in different immunocompromise groups. Comparison

624 between different immunocompromise groups at the same time point was performed using

625 Dunn's test with Benjamini-Hochberg P value adjustment. Comparison of longitudinal antibody

626 changes for participants with two blood draws was performed using the pairwise Wilcoxon rank

627 sum test with Benjamini-Hochberg P value adjustment. Only significant P values were shown.

628 Tukey boxplot was used to summarize antibody levels. Generalized additive model was used to

629 evaluate the trend of antibody development with 95% confidence intervals in the shaded area.

630 Lines between two timepoints indicate the same participants with two blood draws. S-HT,

631 severe hematologic-oncology/transplant; S-A, severe autoimmune/B-cell deficient; NS, non-

632 severe. Severe group included both S-HT and S-A as they had comparable antibody levels at

633 multiple time points.

634

635 **Figure 4. Spike-specific T levels among different immunocompromised groups. a**,

636 enzyme-linked immunosorbent spot (ELIspot) assays using peptide pools derived from

637 ancestral and variant-specific Spike protein. **b**, **c**, CD4<sup>+</sup> T cell (b) and CD8<sup>+</sup> T cell proliferation

638 (c) upon stimulation of ancestral- and variant-specific Spike peptide pools. **d**, Longitudinal

639 trajectory of Spike-specific T levels in different immunocompromise groups. Comparison

640 between different immunocompromise groups at the same time point was performed using

641 Dunn's test with Benjamini-Hochberg P value adjustment. Comparison of longitudinal antibody

642 changes for participants with two blood draws was performed using the pairwise Wilcoxon rank

643 sum test with Benjamini-Hochberg P value adjustment. Only significant P values were shown.  
644 Tukey boxplot was used to summarize antibody levels. Generalized additive model was used to  
645 evaluate the trend of antibody development with 95% confidence intervals in the shade area.  
646 Lines between two timepoints indicate the same participants with two blood draws.

647

648 **Extended Figure 1. Detectable SARS-CoV-2 viral RNA (a) and culturable SARS-CoV-2**  
649 **virus (b) beyond 30 days after symptom onset or first positive PCR/antigen tests,**  
650 **supplemental to Fig. 1.** Fisher's exact test was used to calculate the P values.

651

652 **Extended Figure 2. a,** SARS-CoV-2 intrahost mutations at the amino acid level among different  
653 immunocompromise groups. **b,** Heat map showing distribution of Spike polymorphisms from  
654 participants receiving mAb treatment longitudinally, supplemental to Fig. 2. In the heatmap, y  
655 axis indicates participants' ID (PID) followed by sequential numbers of sample collection, while x  
656 axis shows amino acid positions in the Spike gene. Different domains of Spike are shown at the  
657 top. Colors indicate frequency of polymorphisms, with blue indicating the lowest value and red  
658 indicating the highest value in the scale. Participants in different study groups are separated by  
659 a red horizontal line. mAb resistance mutations are shown by red dotted box.

660

661 **Extended Figure 3. Severe immunocompromise is associated with lower neutralizing**  
662 **antibody levels, supplemental to Fig. 3.** Generalized estimation equation to account for  
663 longitudinal repeated measurements was used to estimate the association between  
664 immunocompromise groups and neutralizing antibody levels against ancestral SARS-CoV-2  
665 Spike protein **(a)** and variant-specific Spike protein **(b)**. Monoclonal antibody (mAb) use, weeks  
666 since symptom onset or first positive PCR/antigen, numbers of vaccinations before enrollment,  
667 sex, and age were adjusted for in these models.

668

669 **Extended Figure 4. Representative T cell proliferation assay gating scheme,**  
670 **supplemental to Fig. 4.** CD4<sup>+</sup> and CD8<sup>+</sup> T cell proliferation results from representative  
671 participants in each immunocompromise group are shown. Non-immunocompromised group,  
672 ID=261 (Omicron, BA.1); Non-severe group (NS), ID= 768 (Omicron, BF.5); Severe-  
673 autoimmune/B-cell deficient (S-A), ID=534 (Omicron, BA.2); Severe- hematological  
674 malignancy/transplant (S-HT), ID= 245 (Delta, B.1.617.2).

Table 1. Demographic and clinical information.

	Immunocompromised (N=56)	Non-Immunocompromised (N=184)	Total (N=240)	P value
Sex, n (%)				0.2
Female	32 (57.1%)	126 (68.5%)	158 (65.8%)	
Male	24 (42.9%)	58 (31.5%)	82 (34.2%)	
Age, Median (Q1, Q3)	55 (45, 67)	46 (33, 59)	49 (34-60)	0.001
Race, n (%)				0.8
Asian	1 (1.8)	10 (5.4)	11 (4.6)	
Black or AA	5 (8.9)	19 (10.3)	24 (10.0)	
Other/Unknown	5 (8.9)	16 (8.7)	21 (8.8)	
White	45 (80.4)	139 (75.5)	184 (76.7)	
Ethnicity				0.5
Hispanic or Latino	5 (8.9)	17 (9.2)	22 (9.2)	
Not Hispanic or Latino	47 (83.9)	143 (77.7)	190 (79.2)	
Other/Unknown	4 (7.1)	24 (13.0)	28 (11.7)	
Inpatient, n (%)	7 (12.5)	8 (4.3)	15 (6.2)	0.051
Number of vaccinations, median number, (Q1, Q3)	3 (3-4)	3 (2-3)	3 (2-4)	<0.001
mAb use, n (%)	24* (42.9)	10 (5.4)	34 (14.2)	<0.001
Antiviral use, n (%)	40 (71.4)	57 (31.0)	97 (40.4)	<0.001
Immunocompromise group, n (%)				<0.001
S-HT	12 (21.4)	0 (0.0)	12 (5.0)	
S-A	13 (23.2)	0 (0.0)	13 (5.4)	
NS	31 (55.4)	0 (0.0)	31 (12.9)	
None	0 (0.0)	184 (100.0)	184 (76.7)	
Symptom duration, median days** (Q1, Q3)	5 (4, 7)	4 (3, 6)	4 (3, 6)	0.04
Variant***				<0.001
Delta	3 (5.4)	43 (23.4)	46 (19.2)	
Omicron	48 (85.7)	137 (74.5)	185 (77.1)	
Other/Unknown	5 (8.9)	4 (2.2)	9 (3.8)	

Q1 and Q3, quartile 1 and quartile 3; AA, African American; mAb, monoclonal antibody; S-HT, severe with malignant hematology or transplant history; S-A, severe autoimmune/B-cell deficient; NS, non-severe immunocompromising condition.

\*, four participants received Mab after blood draws.

\*\*, Symptom duration indicates the duration between symptom onset (patient report or first positive test if asymptomatic screening) and first nasal swab collected by the study group.




\*\*\*, Variant information was obtained by either Spike or whole genome sequencing or by epidemiological information (time period when the participant was infected).

Table 2. Association between immunocompromise groups and SARS-CoV-2 viral decay.

Hazard ratio for SARS-CoV-2 viral RNA clearance				
Group	HR (95% CI)	P	aHR (95% CI)	P
None (Reference)				
S-HT	0.24 (0.10-0.57)	0.001	0.35 (0.13-0.91)	0.03
S-A	0.64 (0.34-1.22)	0.2	0.75 (0.34-1.67)	0.5
NS	0.82 (0.54-1.24)	0.4	0.93 (0.59-1.47)	0.7
Hazard ratio for SARS-CoV-2 culturable virus clearance				
Group	HR (95% CI)	P	aHR (95% CI)	P
None (Reference)				
S-HT	0.28 (0.14-0.56)	0.0004	0.34 (0.15-0.76)	0.009
S-A	0.55 (0.29-1.04)	0.07	0.55 (0.27-1.14)	0.1
NS	1.07 (0.73-1.58)	0.7	1.30 (0.86-1.99)	0.2


HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval.

Age, sex at birth, race, ethnicity, number of vaccinations, monoclonal use, and antiviral use were adjusted for in the multivariate models.




Number at risk

S-HT	12	4	1	0
S-A	13	2	1	1
NS	31	0	0	0
None	184	0	0	0





Number at risk

S-HT	12	3	0	0
S-A	12	1	1	0
NS	31	0	0	0
None	184	0	0	0









Ext. Fig. 1

